Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
January 7, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock code:600276 Stock abbreviation:Hengrui Pharma No.:Lin 2026-004

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Suzhou Suncadia Biopharmaceuticals Co., Ltd.(蘇州盛迪亞生物醫藥有限公司), a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.(江蘇恒瑞醫藥股份有限公司)(the “Company”), received a notice from the National Medical Products Administration (NMPA). Approval was granted for the marketing of the class 1 innovative drug Retlirafusp alfa Injection independently developed by the Company. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug: Retlirafusp alfa Injection

Dosage Form: Injection

Strength: 300mg（6ml）/ bottle

Registered Category: Class 1 Therapeutic Biological Product

Registered Category: CXSS2400101

Prescription/Non-prescription Drug: Prescription Drug

Approved indications: This product in combination with fluorouracil and platinum-based drugs is used for the first-line treatment of locally advanced unresectable, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma that is PD-L1 positive (CPS ≥ 1) by a fully validated test.

II. Other Information of the Drug

There are nearly 1 million new cases of gastric cancer worldwide and more than 655,000 deaths each year[1]. Moreover, the proportion of patients with advanced gastric cancer in China is high, the prognosis is poor, and the situation of disease diagnosis and treatment is more severe[2]. Immunotherapy is currently one of the first-line standard treatment measures for advanced gastric cancer. However, the current immunotherapy has limited improvement in the long-term survival of patients, especially in the refractory population such as the gastric cancer population with liver metastasis. Patients urgently need a reform to the treatment regimen to improve prognosis.

Retlirafusp alfa Injection is an anti-PD-L1/TGF-βRII bi-functional fusion protein independently developed by the Company with intellectual property rights. This product can exert anti-tumor effects by specifically blocking the interaction of PD-1/PD-L1, and at the same time neutralizing TGF-β in the tumor microenvironment. Upon inquiry, it was found that no similar products have been approved for marketing in China and abroad. As of now, the cumulative R&D investment for the related projects of Retlirafusp alfa Injection is about RMB 711.3 million.

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

January 7, 2026

[1].Sundar R,et al. Lancet. 2025 Jun 7;405(10494):2087-2102.

[2].Globocan 2022 (version 1.1) - 08.02.2024.